Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer

DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) — Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Sarah Noonberg, MD, PhD, as Chief Medical Officer. Dr. Noonberg will have key responsibilities to define and advance Prothena`s product pipeline and for leadership of Prothena`s clinical and medical organizations. She succeeds Martin Koller, MD, whose planned retirement from Prothena at the end of 2017 was previously announced.